JB Pharma PAT rises 3.5 percent to Rs 88 crore in Q4

The company had reported a profit after tax (PAT) at Rs 85 crore in the January-March quarter of 2021-22 fiscal.

Revenue of the company stood at Rs 762 crore in the fourth quarter of FY23 as against Rs 625 crore in the same period of FY22, JB Pharma said in a statement.

For the last fiscal, the company reported revenue of Rs 3,149 crore as compared with Rs 2,424 crore in FY22.

During the same period, PAT stood at Rs 410 crore as against Rs 386 crore, recording a growth of 6 per cent, JB Pharma said.

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “JB continued its growth journey in the fourth quarter, thereby ending FY23 with strong performance across business segments. Our market-beating performance in India is pivoted around big brands becoming bigger, and significant demand acceleration in the acquired portfolio. Each of our top 5 brands have ascended through the ranks. Further, Azmarda entered IQVIA’s Top 300 brands list and other acquired business in probiotics and pediatric segment have witnessed rank and market share gain.

Our performance in the International business has seen commendable gains amidst a challenging business environment. International formulations clocked mid-teens growth for the quarter. We continue to witness increased interest from existing and new clients in the CMO business especially in the lozenges segment. We expect to build on this growth in the long term by expanding our pipeline for international business.

While we are cautious of the inflationary environment our efforts are aimed at executing well, with productivity and cost optimization as drivers, in order to deliver improved operating margins”

Read also: JB Pharma acquires leading brand of Rosuvastatin- Razel and combinations